- Lonza has launched the Xcite® AAV stable producer cell line platform to support scalable and robust AAV manufacturing for gene therapy developers.
- The company said the platform demonstrated a 10- to 15-fold increase in titer during beta testing and could reduce manufacturing costs by 80% or more.
Lonza has announced the launch of its Xcite® adeno-associated virus (AAV) stable producer cell line platform, a manufacturing technology designed to support scalability, process robustness, and lower production costs for gene therapy programs.
According to the company, the Xcite® AAV PCL platform uses a proprietary manufacturing approach in which all AAV-producing components are stably integrated into a single cell line. Lonza said the technology is intended to reduce variability, operational complexity, and scale-up challenges associated with transient transfection-based AAV manufacturing processes commonly used in gene therapy production.
The company stated that beta testing using a clinically relevant gene of interest and an engineered capsid demonstrated a 10- to 15-fold increase in titer compared with transient transfection methods. Lonza added that the platform is designed to support programs targeting larger patient populations or higher dosing requirements, including oncology and neurodegenerative disease indications.
“Xcite® AAV PCL platform represents the culmination of years of Lonza innovation and hands-on experience in AAV manufacturing. The technology has the potential to easily scale up processes to reduce COGS by 80% or more through raw material efficiencies, scalable manufacturing, and productivity gains.”
Senthil Ramaswamy, Vice President, Research & Development, Specialized Modalities, Lonza
Lonza said the platform is available through its process development laboratories for manufacturability assessments and early development decision-making. The company added that the technology can also be licensed to developers seeking scalable AAV manufacturing solutions within their own laboratories, expanding its CDMO and contract manufacturing support for gene therapy development.
